Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline
Portfolio Pulse from
Akebia Therapeutics is shifting focus from Auryxia to Vafseo due to declining revenues from Auryxia's patent expiration. Vafseo, approved for dialysis patients, shows early success. A Phase 3 trial for non-dialysis CKD patients is planned for mid-2025 to support label expansion.
February 10, 2025 | 11:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics is focusing on Vafseo due to Auryxia's declining revenues. Vafseo is approved for dialysis patients and shows early success. A Phase 3 trial for non-dialysis CKD patients is planned for 2025.
The shift from Auryxia to Vafseo is significant due to Auryxia's declining revenues. Vafseo's approval and early success in dialysis patients, along with the upcoming Phase 3 trial, indicate potential growth and positive impact on Akebia's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100